[ad_1]
Within eight days, this is the second positive result announced by a pharmaceutical company on its coronavirus vaccine. Last Monday, American Pfizer and German company BioNTech also announced that their vaccine had a 90% prevention rate.
“This positive interim analysis of the third phase of our test provides the first clinical validation that our vaccine can prevent covid-19,” said Stéphane Bancel, CEO of Moderna, adding that we are facing an “extraordinary” time.
The two antidotes have one thing in common: they were designed with an RNA base – ribonucleic acid, which results from the transcription of a sequence of genetic material – using inactive parts of the virus to stimulate the bodies’ immunity. This formula has never been used to produce a vaccine that has received the “green light” from regulatory authorities.
But Moderna’s vaccine remains stable when refrigerated between 2 ° and 8 ° for 30 days, while Pfizer-BioNTech’s vaccine keeps all of its components for only 5 days at these temperatures – to activate your immune system against the virus. it must be between -70º and -80º, which can be an obstacle to its transport and storage.
“Cold transport will be one of the most challenging aspects of applying this vaccine [da Pfizer]”Amesh Adalja, a Johns Hopkins academic, told Reuters last week.” It will be a challenge in all environments because hospitals, even in large cities, do not have storage facilities for a vaccine at this ultra-low temperature, “he said.
Of the 30,000 participants in the third phase of testing, 95 were identified with covid-19, according to the company. Among the infected people, only five people had to receive two doses of the vaccine, known as mRNA 1273.
Now Moderna says it plans to submit its vaccine for approval by the Food and Drug Administration, the government’s regulatory agency, in the coming weeks. This means that by the end of this year there could be two vaccines approved by the North American body.
.
[ad_2]
Source link
